--- title: "Post-Money Valuation, Definition | MedTech Terms" description: "Company valuation immediately after a financing closes. Plain-English Investment & Finance definition for MedTech teams, with examples and related terms." lang: en json-ld: | { "@context": "https://schema.org", "@graph": [ { "@type": "DefinedTerm", "@id": "https://medtechterms.com/terms/post-money-valuation#term", "name": "Post-Money Valuation", "description": "Post-money valuation equals pre-money valuation plus the amount of new capital raised. Investor ownership equals investment ÷ post-money.", "url": "https://medtechterms.com/terms/post-money-valuation", "termCode": "post-money-valuation", "inDefinedTermSet": { "@type": "DefinedTermSet", "name": "MedTech Terms", "url": "https://medtechterms.com/terms" } }, { "@type": "Article", "@id": "https://medtechterms.com/terms/post-money-valuation#article", "headline": "Post-Money Valuation", "description": "Company valuation immediately after a financing closes.", "url": "https://medtechterms.com/terms/post-money-valuation", "mainEntityOfPage": { "@type": "WebPage", "@id": "https://medtechterms.com/terms/post-money-valuation" }, "about": { "@id": "https://medtechterms.com/terms/post-money-valuation#term" }, "articleSection": "Investment & Finance", "inLanguage": "en", "keywords": "Post-Money Valuation, Investment & Finance, medical device, MedTech", "author": { "@type": "Person", "name": "Christian Espinosa", "jobTitle": "Founder, Blue Goat Cyber", "url": "https://bluegoatcyber.com" }, "publisher": { "@type": "Organization", "name": "MedTech Terms", "url": "https://medtechterms.com" }, "isPartOf": { "@type": "WebSite", "name": "MedTech Terms", "url": "https://medtechterms.com" }, "datePublished": "2026-05-05", "dateModified": "2026-05-05", "citation": [ { "@type": "CreativeWork", "name": "PitchBook - MedTech Coverage", "url": "https://pitchbook.com/news/articles/topic/healthtech", "publisher": { "@type": "Organization", "name": "PitchBook" } }, { "@type": "CreativeWork", "name": "NVCA Model Documents", "url": "https://nvca.org/model-legal-documents/", "publisher": { "@type": "Organization", "name": "NVCA" } }, { "@type": "CreativeWork", "name": "Silicon Valley Bank - Healthcare Reports", "url": "https://www.svb.com/trends-insights/", "publisher": { "@type": "Organization", "name": "SVB" } } ], "mentions": [ { "@type": "DefinedTerm", "@id": "https://medtechterms.com/terms/pre-money-valuation#term", "name": "Pre-Money Valuation", "url": "https://medtechterms.com/terms/pre-money-valuation" }, { "@type": "DefinedTerm", "@id": "https://medtechterms.com/terms/dilution#term", "name": "Dilution", "url": "https://medtechterms.com/terms/dilution" } ] }, { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://medtechterms.com/" }, { "@type": "ListItem", "position": 2, "name": "Terms", "item": "https://medtechterms.com/terms" }, { "@type": "ListItem", "position": 3, "name": "Investment & Finance", "item": "https://medtechterms.com/terms?cat=Investment%20%26%20Finance" }, { "@type": "ListItem", "position": 4, "name": "Post-Money Valuation", "item": "https://medtechterms.com/terms/post-money-valuation" } ] }, { "@type": "FAQPage", "@id": "https://medtechterms.com/terms/post-money-valuation#faq", "mainEntity": [ { "@type": "Question", "name": "How does post-money valuation relate to MedTech regulatory compliance?", "acceptedAnswer": { "@type": "Answer", "text": "Post-money valuation reflects the company's total estimated value after receiving new investment. While not a regulatory metric itself, a higher valuation can indicate greater financial resources, which are essential for funding the often-expensive regulatory processes, quality system implementation, and post-market activities required by authorities such as the FDA or under the EU MDR." } }, { "@type": "Question", "name": "Could a low post-money valuation impact a MedTech company's regulatory strategy?", "acceptedAnswer": { "@type": "Answer", "text": "A lower post-money valuation might suggest less capital available. This could force a MedTech company to prioritize regulatory submissions, potentially delaying market entry for certain products or regions, or necessitate more conservative approaches to funding quality management system (QMS) maintenance and post-market obligations outlined in standards like ISO 13485:2016." } }, { "@type": "Question", "name": "Do regulatory bodies consider a company's valuation during product approval?", "acceptedAnswer": { "@type": "Answer", "text": "Regulatory bodies like the FDA or notified bodies under EU MDR focus solely on the safety, effectiveness, and quality of the medical device itself. A company's valuation is not a factor in their review or approval process." } } ] } ] } --- [ MedTech Terms The authoritative reference ](/) Browse Learn [Latest](/latest) About 1. [Home](/) 2. / 3. [Terms](/terms) 4. / 5. [Investment & Finance](/terms?cat=Investment%20%26%20Finance) 6. / 7. Post-Money Valuation [All terms](/terms) Investment & Finance [Startup Lifecycle](/ecosystems/startup-lifecycle) # Post-Money Valuation Company valuation immediately after a financing closes. Reviewed by [Christian Espinosa, Founder, Blue Goat Cyber](/authors/christian-espinosa) Last reviewed May 5, 2026 ## Definition Post-money valuation equals [pre-money valuation](/terms/pre-money-valuation) plus the amount of new capital raised. Investor ownership equals investment ÷ post-money. What the regulation says While 'post-money valuation' is an investment and finance term, its direct impact on regulatory and quality aspects of MedTech is indirect. Regulatory bodies like the FDA or those overseeing EU [MDR](/terms/mdr-reporting) do not directly regulate company valuations. However, a company's valuation can influence its ability to fund significant regulatory submissions, quality system improvements, or [post-market surveillance](/terms/post-market-surveillance) activities, which are critical under regulations like 21 CFR 820 ( [Quality System Regulation](/terms/qsr)) and EU MDR Annex III. ## What this means in practice Post-money is the headline number in press releases. Founders should focus on the [dilution](/terms/dilution) math, not the headline. ## Examples - A MedTech startup with a $100 million post-money valuation successfully secures funding to conduct a pivotal clinical trial required for FDA premarket approval (PMA). - A company's $20 million post-money valuation, while substantial, is carefully managed to ensure adequate funds are reserved for ongoing post-market surveillance activities mandated by EU MDR Article 83. - An investor evaluating a MedTech company with a high post-money valuation examines its cash burn rate to confirm sustained funding for achieving compliance with ISO 13485:2016 quality management system requirements. Common pitfalls - • A high post-money valuation does not guarantee regulatory approval or product market success. - • Confusing a high valuation with adequate funding for long-term regulatory compliance can lead to underestimation of compliance costs. - • Failing to allocate sufficient capital from funding rounds, regardless of valuation, for critical quality and regulatory personnel can hinder compliance. - • Assuming investors fully understand the financial requirements for MedTech regulatory clearances and post-market obligations. ## Frequently asked questions How does post-money valuation relate to MedTech regulatory compliance? Post-money valuation reflects the company's total estimated value after receiving new investment. While not a regulatory metric itself, a higher valuation can indicate greater financial resources, which are essential for funding the often-expensive regulatory processes, quality system implementation, and post-market activities required by authorities such as the FDA or under the EU [MDR](/terms/mdr-reporting). Could a low post-money valuation impact a MedTech company's regulatory strategy? Do regulatory bodies consider a company's valuation during product approval? ## Related terms Grouped by theme ### Editor's picks · Hand-selected related concepts [ Investment & Finance Dilution Reduction in existing shareholder ownership when new shares are issued. ](/terms/dilution)[ Investment & Finance Pre-Money Valuation Company valuation immediately before new money is invested. ](/terms/pre-money-valuation) ### More in Investment & Finance · Same category [ Investment & Finance 409A Valuation An independent fair-market-value appraisal of common stock used to set tax-compliant strike prices for employee stock options. ](/terms/409a-valuation)[ Investment & Finance Anti-Dilution Protection Adjustment that protects investors if the company raises a future round at a lower price. ](/terms/anti-dilution)[ Investment & Finance Bridge Round Interim financing between priced rounds, usually convertible. ](/terms/bridge-round)[ Investment & Finance Burn Rate Rate at which a company spends cash, typically expressed monthly. ](/terms/burn-rate) Cited by Where this term appears across MedTech Terms. Ecosystems (1) - [Startup Lifecycle](/ecosystems/startup-lifecycle) ## Primary references 3 sources Link health: 3 verified · last checked 2026-06-20 PitchBook· 1 NVCA· 1 SVB· 1 1. [1 PitchBook - MedTech Coverage Verified PitchBook · pitchbook.com ](https://pitchbook.com/news/articles/topic/healthtech) 2. [2 NVCA Model Documents Verified NVCA · nvca.org ](https://nvca.org/model-legal-documents/) 3. [3 Silicon Valley Bank - Healthcare Reports Verified SVB · svb.com ](https://www.svb.com/trends-insights/) Inline markers like \[1\] jump to the matching reference above. Sponsor note ### Diligencing a MedTech cybersecurity posture? Blue Goat Cyber supports investors and acquirers with cybersecurity diligence on connected MedTech assets. [Book a 30-minute discovery session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) - No obligation - Expert-led from minute one - NDA available on request MedTech Terms is a community resource sponsored by [Blue Goat Cyber](https://bluegoatcyber.com). Definitions are independent of any vendor. On this term Category Investment & Finance Sources 3 Updated 5/5/2026 [Compare with another term](/compare?a=post-money-valuation) Learn in 60 seconds Card Lesson Quiz Company valuation immediately after a financing closes. - · Post-money is the headline number in press releases. - · Founders should focus on the dilution math, not the headline. - · Investor ownership equals investment ÷ post-money. Remember this Watch out: A high post-money valuation does not guarantee regulatory approval or product market success. Related terms - [Pre-Money Valuation ](/terms/pre-money-valuation) - [Dilution ](/terms/dilution) You may also need Auto-suggested from Investment & Finance and shared keywords. - [409A Valuation ](/terms/409a-valuation) - [Due Diligence ](/terms/due-diligence) - [Milestone-Based Tranche ](/terms/milestone-tranche) - [Term Sheet ](/terms/term-sheet) - [Capitalization Table(Cap Table) ](/terms/cap-table) - [Limited Partner / General Partner(LP / GP) ](/terms/lp-gp) [All Investment & Finance terms](/terms?cat=Investment%20%26%20Finance) MedTech Terms An authoritative, plain-language reference for the regulatory, quality, cybersecurity, and software terms that shape modern medical devices. Browse - [All terms](/terms) - [A–Z index](/a-z) - [Categories](/categories) - [Ecosystems](/ecosystems) - [Learning paths](/paths) - [Compare terms](/compare) - [Quiz](/quiz) Resources - [FDA Medical Devices](https://www.fda.gov/medical-devices) - [EU MDR](https://eur-lex.europa.eu/eli/reg/2017/745/oj) - [IMDRF](https://www.imdrf.org/) - [Methodology](/methodology) - [Changelog](/changelog) - [Editor: Christian Espinosa](/authors/christian-espinosa) - [About this site](/about) © 2026 MedTech Terms. Reference content for educational purposes - not regulatory advice. A community resource sponsored by [Blue Goat Cyber](https://bluegoatcyber.com)